Digital Health Global

APRIL 25, 2024

This pilot study represents a critical step in leveraging digital health technology to enhance cancer treatment outcomes,” said John Wagner, M.D., The study, led by principal investigator Nitin Ohri, M.D., Chief Medical Officer, Koneksa. “By

Health Data 88

Health Data BioTech Drug Development healthcare technology 88

Digital Health Global

AUGUST 2, 2023

Colin’s track record with global biopharma and biotech partners is extensive and admirable,” added Chris Garabedian, a VivoSense Board Member. “He He has consistently worked to improve the speed, safety, and cost-effectiveness of clinical trials through the adoption of new technological solutions.

BioTech 88

BioTech Digital Health Pharmaceuticals healthcare technology 88

Digital Health Global

JUNE 20, 2023

With the additional funding and board appointments, we are set to accelerate the validation of our approach by advancing multiple programs and partnerships toward the ultimate test of any biopharma technology platform – human clinical trials.” Jane Rhodes, Ph.D., Bernd Seizinger, M.D., and Europe.

BioTech 88

BioTech Life Science Leadership Drug Development 88

Healthcare IT Today

OCTOBER 24, 2024

. “Our collaboration with the Association will create valuable opportunities for thousands of members to engage with industry, apply their expertise in new roles, and shape the future of healthcare technology.” MDisrupt has raised $6.6 million to date, including its most recent $3 million in seed funding.

Life Science 124

Life Science Leadership BioTech Connected Health 124

Digital Health Global

MARCH 2, 2023

Koneksa’s digital biomarker solutions capture actionable measures that will enable therapeutic developers to efficiently address pre- and post-market evidence requirements at much earlier stages of development,” said Doug Locke, CEO of SSI Strategy. “We

Life Science 88

Life Science Drug Development BioTech Leadership 88

Digital Health Global

JUNE 13, 2023

The LEARNS study seeks to generate evidence to extend the Koneksa solution to new digital modalities and diseases,” said John Wagner, MD, PhD, Chief Medical Officer, Koneksa. Beacon’s mobile EEG will join more than a dozen digital health technologies that are already integrated into the Koneksa solution.

Drug Development 88

Drug Development eMed BioTech Digital Health 88

Lloyd Price

MAY 5, 2024

Dedicated Facilities: The new EIT Oxford campus includes over 30,000 square meters of research laboratory space, an oncology and wellness clinic, and facilities like AI GPU Supercluster Lab, Drug Design Lab, and Medical Device Lab, specifically dedicated to healthcare technology advancements. Visit www.nelsonadvisors.co.uk

healthcare technology 64

healthcare technology Leadership Life Science BioTech 64